Codman

Discussion in 'Integra Life Sciences' started by anonymous, Feb 22, 2017 at 8:34 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Any insight on the culture / comp?
     

  2. anonymous

    anonymous Guest

    The Codman reps are screwed. You were bought as a commodity. Now Integra owns the majority of that space all that will be needed is someone to manage the pricing on the account, not sell product. Good luck to the Codman and Integra Dural Specialists.
     
  3. anonymous

    anonymous Guest

    You must be a newby. Go ahead and keep thinking that and see where that gets you.
     
  4. anonymous

    anonymous Guest

    Im an Integra rep and that is the dumbest thing i've heard. I hope they cut your ass after that stupid comment, we don't want idiots like you after the deal closes. Each territory will be looked at individually and the best rep will be kept. In some cases, both will be retained.
     
  5. anonymous

    anonymous Guest

    The close of the deal is getting close and no one i know has heard s**t. Great strategy, keep everyone in the dark so that the good reps will leave because we dont want to get screwed...which is what you have to assume will happen. Please, feel free to share info if you have heard ANYTHING...i surely havent.
     
  6. anonymous

    anonymous Guest

    You're making the assumption that Integra gets to keep all the products. I'm not sure the FTC will allow that.
     
  7. anonymous

    anonymous Guest

    The top products from both sides don't compete, therefore it will be a strong bag. The FTC will only ask them to divest competing/cross products. Obviously, they will keep the stronger of the two and get rid of the other.
     
  8. anonymous

    anonymous Guest

    Most are obvious but

    Camino vs ICP express?
    EDS3 vs Accudrain?
    CRAK kits?
    Integra reps vs Codman Reps?
     
  9. anonymous

    anonymous Guest

    I would think the focus is on EDS3, Duraform, and EVD Catheters (without bactiseal)
     
  10. anonymous

    anonymous Guest

    duraform, eds3, & icp express will be divested. Duragen, accudrain are better. Codman doesnt sell icp express anymore now that they have directlink. I think the directlink idea is better than camino...easier to use, much cheaper, all things ICU likes! As far as reps, it will be sorted out between codman and integra upper mgmt. they will compare reps in every territory and share their opinions and then make a call. Depending on a combined dollar amount for a given territory they may keep both. Im excited about the possibilities, i just hope they get it right. It could be a great job!
     
  11. anonymous

    anonymous Guest


    Looks like it's duraform/eds/Camino/Integra shunts on the chopping block.
     
  12. anonymous

    anonymous Guest

    http://investor.integralife.com/releasedetail.cfm?ReleaseID=1039844

    PLAINSBORO, N.J., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a global leader in medical technology, today announced that it has signed a definitive agreement to sell certain neurosurgery assets to Natus Medical for $47.5 million. The divestiture is contingent on the consummation of Integra's proposed acquisition of Codman Neurosurgery from Johnson & Johnson.

    As part of this divestiture, Integra will sell the global Camino® ICP monitoring product line, including its San Diego manufacturing facility, to Natus Medical. The divestiture package also includes certain assets and the U.S. rights relating to Integra's fixed pressure shunts, as well as U.S. rights to Codman's DURAFORM®, standard EVD catheters and CSF collection systems.
     
  13. anonymous

    anonymous Guest

    http://investor.integralife.com/releasedetail.cfm?ReleaseID=1039844

    PLAINSBORO, N.J., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a global leader in medical technology, today announced that it has signed a definitive agreement to sell certain neurosurgery assets to Natus Medical for $47.5 million. The divestiture is contingent on the consummation of Integra's proposed acquisition of Codman Neurosurgery from Johnson & Johnson.

    As part of this divestiture, Integra will sell the global Camino® ICP monitoring product line, including its San Diego manufacturing facility, to Natus Medical. The divestiture package also includes certain assets and the U.S. rights relating to Integra's fixed pressure shunts, as well as U.S. rights to Codman's DURAFORM®, standard EVD catheters and CSF collection systems.
     
  14. anonymous

    anonymous Guest

    It sounds like us reps will know our future at the end of this week. All of the managers were told on Friday who is staying and who isnt. Mgr meeting in NJ his week should finalize the reps & territories. Anyone hearing anything different?
     
  15. anonymous

    anonymous Guest

    So what was the rational to determine which rep stayed and which rep lost their job? Seems to be weighted more towards Integra reps than Codman.
     
  16. anonymous

    anonymous Guest

    Integra had a bigger sales force so they lost more reps but still out number Codman reps even after the cuts. As far as the criteria, who knows, im sure a lot of factors were considered. For the most part, I like everything I heard from the meeting. Its going to be a change for everyone but once everyone settles in I think it will be a really good job.
     
  17. anonymous

    anonymous Guest

    I do believe that there are some good Codman reps out there but I still believe they will struggle under Integra’s leadership and sales processes. You guys better get comfortable selling capital and being managed by threat of losing your job real quick, otherwise it’s going to be a tough year.
     
  18. anonymous

    anonymous Guest

    I agree. It's definitely going to be a change for all of us and some will adapt, some won't. I just hope they give us time to do so. You are going from one end of the spectrum to the other as far as cultures are concerned. I like Integra's 'let's make it happen' approach so far.